BioKangtai: Quadrivalent influenza virus split vaccine (for the population aged 6-35 months) has initiated Phase I clinical trials

According to the Zhitong Finance APP, BioKangtai (300601.SZ) announced that the Phase I clinical trial preparation for its quadrivalent influenza virus split vaccine (for the 6-35 month age group) has been completed, and the Phase I clinical trial has commenced, with the first subject successfully enrolled recently. This quadrivalent influenza virus split vaccine, which has entered Phase I clinical trials, is suitable for the 6-35 month age group and can stimulate the body to produce immunity against influenza viruses, used for the prevention of influenza caused by vaccine-related strains